Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRC105 in Metastatic CRPC
NCT01090765Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2010
- Primary completion
- Apr 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of carotuximab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by National Cancer Institute. Started Feb 2010; status: completed.
02
Drugs
carotuximab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01090765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01090765.